18423-89-7

Basic information

• Product Name: 2,6-dideoxy-3-C-methyl-3-O-methyl-L-arabino-hexopyranose
• CAS NO: 18423-89-7
• Molecular Weight: 176.213
• Mol File: 18423-89-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2,6-dideoxy-3-C-methyl-3-O-methyl-L-arabino-hexopyranose(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dideoxy-3-C-methyl-3-O-methyl-L-arabino-hexopyranose(18423-89-7)
• EPA Substance Registry System: 2,6-dideoxy-3-C-methyl-3-O-methyl-L-arabino-hexopyranose(18423-89-7)

Safety Data

• Hazardous Substances Data: 18423-89-7(Hazardous Substances Data)

Upstream product

• 137101-02-1 methyl 2,6-anhydro-4-O-benzyl-3-C-methyl-2-thio-β-L-mannopyranoside 
• 137172-14-6 methyl 2,6-dideoxy-3-C-methyl-3-O-methyl-β-L-arabino-hexopyranoside 
• 81103-11-9 clarithromycin 
• 83905-01-5 Zithromax(R) 
• 144604-03-5 (10E)-10,11-didehydro-11-deoxy-6-O-methylerythromycin 
• 1092077-36-5 C₈H₁₄O₄ 
• 78443-22-8 C₃₇H₆₉ClN₂O₁₂ 
• 78443-20-6 4-O-acetyl-1-deoxy-1-(2-pyridylthio)-α-L-cladinoside 
• 26116-56-3 erythromycylamine 
• 30760-16-8 9-deoxo-9-iminoerythromycin A 
• 97562-21-5 5-O-benzyl-4-O-(benzyloxymethyl)-2,6-dideoxy-3-C-methyl-3-O-methyl-L-ribohexose 
• 114-07-8 erythromycin 

Downstream Products

• 121203-04-1 1,4-di-O-phenoxyacetyl-β-L-cladinose 
• 121203-17-6 1-deoxy-4-O-phenoxyacetyl-1-(2-pyridylthio)-β-cladinoside 
• 121203-06-3 1-deoxy-4-O-phenoxyacetyl-1-(2-pyridylthio)-α-cladinoside 
• 121230-89-5 2',4',4''-tri-O-acetyl-3-O-(4-O-phenoxyacetyl-α-L-cladinosyl)desmycosin 
• 121230-91-9 2',4',4''-tri-O-acetyl-20-deoxo-3-O-(4-O-phenoxyacetyl-α-L-cladinosyl)desmycosin 
• 121231-05-8 2',4',4''-tri-O-acetyl-19-deformyl-3-O-(4-O-phenoxyacetyl-α-L-cladinosyl)desmycosin 
• 121203-05-2 Phenoxy-acetic acid (2S,3S,4R)-6-hydroxy-4-methoxy-2,4-dimethyl-tetrahydro-pyran-3-yl ester 

Relevant articles and documents

PROCESS FOR THE PRODUCTION OF TELITHROMYCIN

The present invention relates to a process for the preparation of erythromysin derivatives, in particular telithromycin of formula (I) and its pharmaceutically acceptable salts, providing the isolated intermediates in crystalline form of superior stability and purity.

Antibiotic agents

Methods of treating a microbial infection comprising administering to a patient in need of such treatment are disclosed. In one aspect the method comprises administering to a patient in need of such treatment a therapeutically effective amount of Erythromycin B (or a pharmaceutically acceptable derivative thereof). In another aspect the method comprises a pharmaceutical composition comprising at least 50% by weight of Erythromycin B (or a pharmaceutically acceptable derivative thereof) of the total weight of antibiotic present in the composition. Also disclosed are 2′-esters of Erythromycin B and Erythromycin B enol ether.

De novo highly stereocontrolled synthesis of 2,6-dideoxy sugars by use of 2,6-anhydro-2-thio sugars

Representative 2,6-dideoxy sugars, L-cladinose (1), L-(mycarose (2), L-oleandrose (3), L-olivose (4), and all of their C-3 epimers, 2,6-dideoxy-3-C-methyl-3-O-methyl-L-arabino-hexopyranose (26), 2,6-dideoxy-3-C-methyl-L-arabino-hexopyranose (L-olivomycose